Related Experiment Videos
Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction
Insights
Early cardiac catheterization and revascularization improve survival for acute myocardial infarction (AMI) patients with left ventricular dysfunction (LVD). Patients without LVD showed similar outcomes regardless of invasive or conservative treatment.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Outcomes
Background:
- Acute myocardial infarction (AMI) with left ventricular dysfunction (LVD) is linked to poor prognosis.
- Revascularization may improve survival in AMI patients, but evidence for stable patients with LVD post-AMI is limited.
Purpose of the Study:
- To determine if early catheterization and revascularization improve survival in thrombolysis-treated AMI patients with significant LVD.
- To compare outcomes between invasive and non-invasive strategies in this patient group.
Main Methods:
- Analysis of 737 patients from the ARGAMI-2 trial with LVD assessed by echocardiography.
- Comparison of mortality rates between patients undergoing cardiac catheterization and revascularization versus non-invasive treatment within 30 days post-AMI.
Main Results:
- Patients with significant LVD undergoing invasive procedures showed reduced 30-day (4.3% vs 10.6%) and 6-month (6.1% vs 15.5%) mortality compared to non-invasive treatment.
- Patients without significant LVD had similar mortality rates (30-day and 6-month) for both invasive and non-invasive approaches.
Conclusions:
- Early cardiac catheterization and revascularization appear beneficial for AMI patients with significant LVD.
- In AMI patients without significant LVD, early invasive treatment yielded similar outcomes to conservative management.
Background:
Acute myocardial infarction (AMI) associated with significant left ventricular dysfunction (LVD) indicates a poor prognosis. Previous studies suggested that revascularization improves survival of patients with AMI complicated by cardiogenic shock. However, other studies that suggested that revascularization improves survival of stable patients with significant LVD did not specifically address patients who had recently had an AMI.
Objectives:
Our purpose was to determine whether patients with thrombolysis-treated AMI associated with significant LVD are likely to incur a survival advantage from catheterization and coronary revascularization performed within 30 days after AMI.
Methods:
The study population was drawn from the Argatroban in Acute Myocardial Infarction-2 (ARGAMI-2) trial, which included 1200 patients with AMI, all of whom received thrombolytic therapy. Our analysis included 737 patients for whom LV function was estimated by echocardiography. Two hundred two patients had significant LVD; of them, 117 (58%) underwent cardiac catheterization and 85 were treated noninvasively. Among 535 patients without significant LVD, 291 (54%) underwent cardiac catheterization and 244 were treated noninvasively.
Results:
Compared with a noninvasive approach, an invasive approach resulted in reduced 30-day and 6-month mortality rates in patients with significant LVD: 4.3% versus 10.6%, adjusted odds ratio (OR) 0.26, 95% confidence interval (CI) 0.04 to 1.18, and 6.1% versus 15.5%, OR 0.27, 95% CI 0.06 to 0.98, respectively. A similar comparison in patients without significant LVD resulted in comparable 30-day and 6-month mortality rates for both patient groups: invasively versus noninvasively treated, 0.7% versus 0.8%, OR 1.04, 95% CI 0.04 to 12.7, and 1.4% versus 1.7%, adjusted OR 1.60, 95% CI 0.20 to 9.87.
Conclusions:
The current study suggests that AMI patients with significant LVD may benefit from cardiac catheterization and revascularization performed early after AMI, whereas in patients without significant LVD the outcome of those treated invasively or conservatively was similar.